drugset / Trial / NCT06241781
Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase II, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of Autologous Tumor Infiltrating Lymphocytes (GT101 injection) compared with Gemcitabine in participants with recurrent or metastatic cervical cancer.
Timeline
- Start
- 2024-04-02
- Primary completion
- 2027-01-31
- Completion
- 2027-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GT101 | Cell therapy | — | — |
| Comparator | Gemcitabine | Small molecule | — | — |
Indications
No indication recorded.